The Motley Fool
02 Aug 2026, 11:55 UTC · 7w ago
Verdict
Headline takes no side. We score LLY +0.70 across four claims — strongly bullish.
+0.70strongly bullish
More positive than 78% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Eli Lilly reported a massive 44.7% year-over-year revenue increase in FY 2025, reaching approximately $65.2 billion.
So whatExtreme top-line growth driven by high-demand obesity and diabetes drugs is a primary driver for valuation and risk appetite in the biotech sector.
More positive than 99% of claims this week
Eli Lilly exhibits high customer concentration risk, relying heavily on three major wholesalers: McKesson, Cencora, and Cardinal Health.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 87% of claims this week
Abbott Laboratories grew revenue by 5.7% to nearly $44.3 billion in FY 2025 with a net income of roughly $6.5 billion.
More positive than 62% of claims this week
Abbott Laboratories maintains a conservative financial structure with a debt-to-equity ratio of approximately 0.3x and a current ratio of 1.6x.
More positive than 50% of claims this week
Which stocks this story touches
More positive than 78% of ticker scores this week
Highlighted as a powerhouse with massive revenue surges driven by breakthrough obesity and diabetes treatments.
More positive than 72% of ticker scores this week
Described as a diversified healthcare giant with steady growth, strong free cash flow, and a conservative financial structure.
Near neutral — 91% of ticker scores this week are stronger
Mentioned only as a wholesaler that Eli Lilly depends on, without specific positive or negative news for Cardinal Health itself.
Near neutral — 91% of ticker scores this week are stronger
Mentioned only as a wholesaler that Eli Lilly depends on, without specific positive or negative news for Cencora itself.
Near neutral — 91% of ticker scores this week are stronger
Mentioned only as a wholesaler that Eli Lilly depends on, without specific positive or negative news for McKesson itself.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
More positive than 76% of relationship scores this week
[a_to_b] Cencora is one of three major wholesalers that Eli Lilly depends heavily on for distribution.
More positive than 76% of relationship scores this week
[a_to_b] McKesson is one of three major wholesalers that Eli Lilly depends heavily on for distribution.
More positive than 17% of relationship scores this week
[mutual] The article compares the two as healthcare investment options, though they operate in different primary segments (diversified medical devices vs. pharmaceutical growth).
+1.9%
Price agrees with the score
$1170.48 vs $1148.84 close before publication (Jul 31) · not market-adjusted
LLY chart →
